Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factor IX replacement in surgery and prophylaxis.

Anaadriana Zakarija1

  • 1Department of Hematology/Oncology, Northwestern University, Chicago, Illinois, USA. z-anaadriana@northwestern.edu

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|August 24, 2004
PubMed
Summary

Treatment for hemophilia B requires personalized pharmacokinetic studies to optimize factor IX product use. Individualized plans are crucial for high-risk situations and prophylaxis, considering safety, cost, and availability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura.

British journal of haematology·2023
Same author

Hereditary thrombotic thrombocytopenic purpura acquired through liver transplantation: A case report.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2023
Same author

Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency.

Bone·2020
Same author

NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018.

Journal of the National Comprehensive Cancer Network : JNCCN·2018
Same author

Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.

International journal of hematology·2015
Same author

Cancer-Associated Venous Thromboembolic Disease, Version 1.2015.

Journal of the National Comprehensive Cancer Network : JNCCN·2015

Area of Science:

  • Hematology
  • Pharmacokinetics
  • Factor Replacement Therapy

Background:

  • Hemophilia B treatment involves factor IX replacement therapy.
  • Patient responses to factor IX products can vary significantly.
  • High-risk settings, such as surgery, require careful treatment planning.

Observation:

  • Differences exist in the recovery of various factor IX products.
  • Individual patient pharmacokinetic profiles influence treatment outcomes.
  • Plasma-derived and recombinant factor IX concentrates have distinct characteristics.

Findings:

  • Individual pharmacokinetic studies are essential for determining optimal treatment regimens.
  • Personalized treatment programs improve outcomes in hemophilia B patients.

Related Experiment Videos

  • Variability in patient response necessitates tailored therapeutic strategies.

    • Implications:

    • Pharmacokinetic profiling enables precise dosing for hemophilia B management.
    • Tailored treatment plans enhance safety and efficacy in high-risk scenarios.
    • Informed decisions regarding factor IX product selection consider safety, cost, and availability.